Gastric Cancer
1,804
319
413
663
Key Insights
Highlights
Success Rate
85% trial completion
Published Results
156 trials with published results (9%)
Research Maturity
663 completed trials (37% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
6.4%
115 terminated out of 1804 trials
85.2%
-1.3% vs benchmark
11%
200 trials in Phase 3/4
24%
156 of 663 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 663 completed trials
Clinical Trials (1804)
Study for AZD4360 in Participants With Advanced Solid Tumours
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.
Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Modulated Mid-frequency Whole-body Electromyostimulation and Nutritional Therapy in Gastrointestinal Cancer Patients
Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma
IDOV-Immune for Advanced Solid Tumors
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Reconstruction With a Lawrence-Hunt Jejunal Pouch After Total Gastrectomy
How Epigenetic Changes in hMLH1 Connect Lab Research With Diagnosis in Gastric Cancer
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer